year in Medical Technology

British Woman Celebrates a Year of Living Cancer-Free

LONDON, July 30 /PRNewswire/ -- It's been a year since fashion designer Joanne Scott went through a cancer treatment that changed her life -- and made history to boot. Ms. Scott, 54, was the first person in the world to receive an injection of tumor-activated natural killer (...

Montefiore Medical Center and Albert Einstein College of Medicine Herald New Agreement To Continue Forty-Plus Year Historic Relationship

New agreement outlines an increased level of commitment to clinical care, research and education NEW YORK, July 30 /PRNewswire-USNewswire/ -- Montefiore Medical Center and Albert Einstein College of Medicine of Yeshiva University today announced a new ten-year agreement to continue t...

IMPACT Study Showed Longer Valcyte(R) (valganciclovir hydrochloride tablets) Treatment Demonstrated Better Protection Against Cytomegalovirus (CMV) Disease One Year Post-Transplant

CMV is the most serious viral infection affecting transplant patients BOSTON, June 1 /PRNewswire/ -- New Phase III study results presented for the first time today at the ninth annual American Transplant Congress 2009 (ATC) demonstrate that doubling the duration of preventive therapy ('prop...

Taking Folic Acid for a Year Before Pregnancy May Reduce Risk of Preterm Birth

Findings Reinforce March of Dimes Message: Start Taking a Vitamin with Folic Acid Before Pregnancy WHITE PLAINS, N.Y., May 11 /PRNewswire-USNewswire/ -- Women who take folic acid supplements for at least one year before they become pregnant may cut their risk of having a premature baby by hal...

First Year Results of the AXA Research Fund: Over Euro 13 Million Allocated for Research in 2008

PARIS, March 24 /PRNewswire-FirstCall/ -- The AXA Research Fund closed out its first year of existence. During the year ended, the Fund granted more than Euro 13 million to various European research institutions. The purpose of the Fund is to promote the understanding and prevention of major ...

Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update

- Conference Call Today at 5:00 p.m. Eastern Time - SOUTH SAN FRANCISCO, Calif., March 16 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ), a biopharmaceutical company focused on oncology, today reported financial results for the fourth quarter and year ended Decembe...

The Quigley Corporation Licenses Naturally Derived Compound For Scar Improvement; License Requires Payments Totaling $1.1 Million To The Quigley Corporation Over A Five Year Period For Exclusive Ownership

DOYLESTOWN, Pa., Feb. 24 /PRNewswire-FirstCall/ -- The Quigley Corporation (Nasdaq: QGLY ) www.quigleyco.com , today announced that it has signed a license with assignment of ownership agreement for its patented formulation QR-340 developed by its wholly owned subsidiary, Quigley Pharma Inc. T...

Pharmasset Reports Fiscal Year End 2008 Financial Results

PRINCETON, N.J., Dec. 11 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS ), a clinical stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections, reported financial results for the fiscal year ended September 30, 2008. At...

Ikaria(R) Named Private Company of the Year by New Jersey Technology Council

CLINTON, N.J., Nov. 21 /PRNewswire/ -- Ikaria Holdings, Inc. today announced that it has been named Private Company of the Year by the New Jersey Technology Council (NJTC), a 1,200-member non-profit organization that provides business support, networking opportunities, information and advocacy for...

Unprecedented 8th Year Start Up of National Direct AmeriCorps Program Access to Care Through Service (ACTS) Parent, Lead Organization The Philadelphia AIDS Consortium and World Health Care Infrastructures

PHILADELPHIA, Sept. 30 /PRNewswire-USNewswire/ -- The following is being released by The Philadelphia AIDS Consortium: WHO: Parent Organization: The Philadelphia AIDS Consortium in partnership with its network of eleven (11) community-based organization sites located throughout the tri-state...

Screening for Ischemia in Asymptomatic Patients With Type 2 Diabetes: Five- Year Outcomes in the DIAD Study

Study Shows Systematic Screening May Not Be Necessary For Diabetic Patients BOSTON, Sept. 13 /PRNewswire-USNewswire/ -- There are 21 million patients with Type 2 diabetes in the United States alone. Coronary artery disease (CAD) is a major cause of morbidity in patients with diabetes. Silent myo...

Velos Set to Clear 50 Percent Market Penetration of Large U.S. Clinical Research Sites by Year End

FREMONT, Calif., Aug. 7 /PRNewswire/ -- Velos, Inc., the recognized leader and trusted resource for clinical trial management information systems for large investigator sites, today announced it will cross the 50 percent market penetration threshold by year end. The company's flagship product,...

ImQuest Receives Two Year Phase 2 SBIR Grant to Develop Pyrimidinedione Product as an Anti-HIV Topical Microbicide

FREDERICK, Md., July 29 /PRNewswire/ -- ImQuest BioSciences announced today the successful acquisition of funding from the National Institute of Allergy and Infectious Disease (NIAID/NIH) to support the development of pyrimidinedione inhibitors as topical microbicides to prevent the sexual tra...

Malaria Vaccine Developer Sanaria Inc. Receives the Technology Council of Maryland's Emerging Company of the Year Award

ROCKVILLE, Md., May 19 /PRNewswire-USNewswire/ -- On Thursday May 15, 2008 Sanaria Inc. was named Emerging Company of the Year at the annual Technology Council of Maryland's Tech Awards Celebration honoring the state's technology leaders and organizations. http://techcouncilmd.com/News/tcmn...

NeoVista Presents One Year Data on Novel Wet AMD Therapy at Macula Society

Data Analysis Shows Promise of Epiretinal Brachytherapy as NeoVista Progresses with Phase III CABERNET Study PALM BEACH, Fla., March 28 /PRNewswire/ -- NeoVista, Inc. released today to the eye community updated results from a one-year feasibility study of the company's novel e...

Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights

BERKELEY HEIGHTS, N.J., March 12 /PRNewswire-FirstCall/ -- Genta Incorporated (Nasdaq: GNTA ) today announced financial results and progress for the quarter and year ended December 31, 2007. The Company noted significant recent milestones, including: -- AGENDA Phase 3 trial using key b...

Memory Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results

- Completes SAD Portion of the Phase 1 Program for R4996/MEM 63908 - MONTVALE, N.J., March 6 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (Nasdaq: MEMY ), a biopharmaceutical company focused on the discovery and development of innovative drug candidates for the treatment of a broa...

Financial Results for Full Year 2007: NicOx Significantly Advances Clinical Programs

SOPHIA ANTIPOLIS, France, March 3 /PRNewswire-FirstCall/ -- NicOx S.A. (Euronext Paris: COX) today announced its financial results for 2007 and provided an overview of its activities during the year. NicOx also announced today the initiation of two large Ambulatory Blood Pressure Monitoring (A...

Three Year Analysis of Treatment Efficacy, Cosmesis, and Toxicity Support use of the Hologic Mammosite Radiation Therapy System

American Society of Breast Surgeons Study Represents Largest Patient Population to Date BEDFORD, Mass., Feb. 25 /PRNewswire-FirstCall/ -- Hologic, Inc. (Nasdaq: HOLX ) a diversified medical technologies company specializing in imaging systems, diagnostics, and inter...

FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria

BRUSSELS, Belgium, and BRIDGEWATER, N.J., Feb. 19 /PRNewswire-FirstCall/ -- UCB (Euronext: UCB) and sanofi-aventis announced today that the U.S. Food and Drug Administration (FDA) approved a New Drug Application (NDA) for XYZAL(R) (levocetirizine dihydrochloride) 0.5 mg/mL oral solution, a pre...

Huge Drop in Preterm Birth-Risk Among Women Taking Folic Acid One Year Before Conception

Largest U.S. Study of Pre-conceptional Folic Acid Supplementation Receives March of Dimes Award DALLAS, Jan. 31 /PRNewswire-USNewswire/ -- New research suggests that women who take folic acid supplements for at least one year before they become pregnant can cut their risk of having a prema...

One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function

-- When compared to insulin glargine, exenatide offered added benefits of weight loss and improved beta-cell function when used with metformin -- AMSTERDAM, Netherlands, Sept. 21 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ) and Eli Lilly and Company (NYSE: LLY ) to...

One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function

-- When compared to insulin glargine, exenatide offered added benefits of weight loss and improved beta-cell function when used with metformin -- AMSTERDAM, Netherlands, Sept. 21 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ) and Eli Lilly and Company (NYSE: LLY ) to...

New Study Demonstrates 4 Year Olds Fed Enfamil LIPIL(R) as Infants Have Brain and Eye Outcomes Similar to Breastfed Babies

Reinforces Importance of DHA/ARA in Infant Diet EVANSVILLE, Ind., Sept. 18 /PRNewswire-FirstCall/ -- A recently published study of 4 year olds who had been fed Enfamil LIPIL infant formula exclusively for their first 17 weeks of life has become the longest-term analysis of its kind...

Sixty-One Percent of Newly Diagnosed Parkinson's Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis

Levodopa Remains the Most Widely Prescribed Drug for Parkinson's Disease, According to a New Report from Decision Resources WALTHAM, Mass., Aug. 13 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issu...

Next Generation Proton Therapy System for Cancer Treatment Set for Release This Year

LITTLETON, Mass., Feb. 26 /PRNewswire/ -- Still River Systems announced today the successful operation of the world's highest field, high energy cyclotron magnet. Still River's magnet is the key technical element for reducing the size and cost of the particle accelerator that will deliver proton t...

CVS Caremark Study Finds Non-Adherent Heart Failure Patients Almost Twice as Likely to be Re-Hospitalized Within a Year

CVS Caremark Proactive Pharmacy Care approach designed to help improve medication adherence to positively impact outcomes and manage costs WOONSOCKET, R.I., Feb. 3 /PRNewswire/ -- A study released today by CVS Caremark (NYSE: CVS ) found that nearly half of patients hospitalized for he...

CV Therapeutics Announces Archives of Internal Medicine Publication of Study Showing 20 Percent of Heart Attack Patients in Premier Registry Experienced Angina at One Year

-Study shows angina at one year associated with significantly higher incidence of depression- PALO ALTO, Calif., June 23 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX ) today announced that the Archives of Internal Medicine published results of a major...

Medivation's Dimebon(TM) Significantly Improved Thinking and Memory in Alzheimer's Disease Patients Over One Year

- Cognitive Function Data from Pivotal Trial Presented at American Academy of Neurology 60th Annual Meeting - SAN FRANCISCO and CHICAGO, April 17 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN ) today announced that Alzheimer's patients treated with the investigatio...

CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year

Two Large Phase III Trials Confirm Robust Efficacy of CIMZIA BOSTON, Nov. 7 /PRNewswire/ -- UCB announced today the results of new Phase III data from the RAPID 1 and 2 studies presented at the American College of Rheumatology Annual Scientific Meeting (ACR), which show CIMZIA(R) (certol...

Despite Serious Health Risks, One in Three Adults with Heart Disease Does Not Believe They Need a Flu Shot This Year

DALLAS, Nov. 1 /PRNewswire-USNewswire/ -- Death resulting from influenza, often referred to as "the flu," is more common among individuals with heart disease than among patients with any other chronic medical condition. However, according to a new nationwide survey of heart disease patients co...

Over 10,000 UK Breast Cancer Patients Could Become Eligible Within the Next Year for a Breast Cancer Therapy Showing Increased Survival Rates, Reveals Synovate Healthcare’s European Oncology Monitor

LONDON, April 4, 2007--Treatment data from Synovate Healthcare’s European Oncology Monitor reveals that over 10,000 breast cancer patients in the UK could become eligible for a breast cancer treatment showing lower death rates in patients. The treatment was the subject of a recent study deta...

Remicade Two Year Data in Ankylosing Spondylitis Show Improvement in Spinal Mobility and Spinal Inflammation

Findings from the ASSERT Trial Presented at EULAR BARCELONA, Spain, June 15, 2007 /PRNewswire-FirstCall/ -- Data presented today at the European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology showed that patients with ankylosing spondylitis (AS) who received REMICADE(R)...

GenoMed Prevents Sickle Cell Pain for Over a Year

ST. LOUIS--(BUSINESS WIRE)--Mar 12, 2007 - GenoMed (OTC Pink Sheets:GMED), the Next Generation Disease Management company whose business is public health(TM), announced today publication of a case report of a sickle cell patient whose pain has disappeared for over a year thanks to GenoMed's treatme...

Sanofi Pasteur Submits Supplemental Application for A(H1N1) Pandemic Vaccine to U.S. FDA

...hose listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in sanofi-aventis' annual report on Form 20-F for the year ended December 31, 2008. Other than as required by applicable law, sanofi-aventis does not undertake any obligation to update or revise any forward-lo...

Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009

...nical trials already initiated on three drugs this year Expand pipeline by moving at least two addi...e new drug has already moved into development this year Financial Results On a GA... using the tax benefits generated from its current year loss from continuing operations to offset a portio...

Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership

...reate a diabetes drug discovery and development platform. The four-year program is one of the largest and most comprehensive collaborations in the 40 year history of JDRF, a leader in setting the agenda for diabetes research worldwide and the largest charitable funder and advocate of type 1 research. ...

NewCardio Announces Master Services Agreement With Dedicated Phase I

...ing statements due to numerous factors, including the potential risks and uncertainties set forth in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2008 and relate to our business plan, our business strategy, development of our proprietary technology platform and our products, t...

Nektar Therapeutics Reports Second Quarter 2009 Financial Results

...s of $33.4 million or $0.36 per share in the second quarter of 2008. Nektar made improvements to its operating efficiencies as compared to a year ago. Total operating costs and expenses were down 19% to $43.5 million in the second quarter of 2009 as compared to $53.8 million in the second quart...

Study Shows Brain Fitness can Save Medicare Billions

...ctual healthcare costs to SF-36 scores. The researchers found that a year following training with the brain fitness software, now owned and marketed ... those patients had lower predicted healthcare costs by about $143 less per year (or $128 on an unadjusted basis.) "This data indicates that we can h...